Genolife

Sexually Transmitted Disease Screening

Detection and typing of Human Papillomavirus (HPV)

$1,650 MXN
  • 44 viral subtypes analyzed
  • High risk (HR):16, 18, 26, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73 and 82
  • (BR): 6, 11, 13, 32, 40, 42, 43, 44, 54, 55, 57, 61, 62, 64, 69, 71, 72, 81, 83, 84, 87, 89 y 90
  • Technique: PCR. Type: qualitative (detection)

Sexually Transmitted Disease Panel (STD-3)

$1,890 MXN
  • Herpes Simplex Virus 1
  • Herpes Simplex Virus 2
  • Chlamydia trachomatis

Sexually Transmitted Disease Panel (STD-4)

$2,350 MXN
  • Human papillomavirus (HPV) 44 subtypes
  • Chlamydia trachomatis
  • Herpes Simplex Virus 1
  • Herpes Simplex Virus 2

Panel de Enfermedades de Transmisión Sexual (ETS-6) HOMBRE

$2,400 MXN
  • Human papillomavirus (HPV) 44 subtypes
  • Herpes Simplex Virus 1
  • Herpes Simplex Virus 2
  • Mycoplasma genitalium
  • Ureaplasma urealyticum
  • Neisseria gonorrhoeae

Sexually Transmitted Diseases Panel (STD-7)

$2,700 MXN
  • Human papillomavirus (HPV) 44 subtypes
  • Chlamydia trachomatis
  • Herpes Simplex Virus 1
  • Herpes Simplex Virus 2
  • Neisseria gonorrhoeae
  • Trichomonas vaginalis
  • Mycoplasma genitalium

Sexually Transmitted Disease Panel (STD-8)

$3,000 MXN
  • Human papillomavirus (HPV) 44 subtypes
  • Neisseria gonorrhoeae
  • Herpes Simplex Virus 1
  • Herpes Simplex Virus 2
  • Mycoplasma genitalium
  • Trichomonas vaginalis
  • Ureaplasma urealyticum
  • Chlamydia trachomatis

Sexually Transmitted Disease Panel (STD-11)

$3,100 MXN
  • Human papillomavirus (HPV) 44 subtypes
  • Neisseria gonorrhoeae
  • Herpes Simplex Virus 1
  • Herpes Simplex Virus 2
  • Mycoplasma genitalium
  • Trichomonas vaginalis
  • Ureaplasma urealyticum
  • Chlamydia trachomatis
  • Treponema pallidum
  • Mycoplasma Hominis
  • Ureaplasma parvum
Process for performing the study

At Genolife, we perform virus detection from samples obtained through urethral and cervicovaginal exudate.

Técnica: PCR (reacción en cadena de la polimerasa) VPH genotipado (21AR Y 23 BR)

Type: qualitative (detection)

Indicaciones para la toma de muestra exudado uretral o cervicovaginal (VPH / ETS):

No usar óvulos, cremas ni duchas vaginales por lo menos 24 horas antes.
No usar medicamentos tópicos en la zona a evaluar por lo menos 24 horas antes.
No tener relaciones sexuales 72 horas previas a la toma.
No realizar aseo íntimo agresivo el día de la toma.
En hombres, se indica no orinar al menos 2 hora antes de la toma uretral.
En caso de estar en tratamiento antibiótico, esperar al menos 7 días después de terminarlo para tomar la muestra.

Contact us to schedule your appointment